Rights and permissions
About this article
Cite this article
Greater QOL with carboplatin/paclitaxel than cisplatin/etoposide in NSCLC. Pharmacoecon. Outcomes News 484, 13 (2005). https://doi.org/10.2165/00151234-200504840-00032
Published:
Issue Date:
DOI: https://doi.org/10.2165/00151234-200504840-00032